Spotlight on Efflux and Uptake Drug Transporters in In Vitro Drug-Drug Interaction Studies

What are drug transporters?

Drug transporters are membrane-bound proteins that assist in the movement of drugs into or out of cells. Drug transporters are found in all cells throughout the body, but drug developers and ADME scientists are mainly concerned with transporters located in the liver, intestines, kidneys and the blood-brain barrier when considering drug-drug interactions (DDIs).

Drug transporters can be split into two superfamilies. The first are the ATP-binding cassette (ABC) transporters, also known as efflux transporters. Efflux transporters use energy released from the hydrolysis of ATP to actively move compounds from inside to outside the cell. The main efflux transporters are:

• P-gp (MDR1)
• BCRP
• BSEP
• MRPs

The second superfamily of transporters are the solute carrier (SLC) transporters, also called uptake transporters. These transporters do not require ATP and are responsible for moving compounds from outside to inside the cell. Some of the main uptake transporters are:

• OATP1B1/3
• OCT1/2
• OAT1/3
• MATE1/2K

Transporter Expression and Function

The focus on specific transporters generally depends on which tissue are being evaluated. For example, when considering the intestine and blood-brain barrier, efflux transporters – especially P-gp and BCRP – are important because they regulate the absorption, or entry, of drugs into the brain or into the cells of the intestine. Efflux transporters are also involved in pumping compounds into the bile or urine for excretion. When looking at the liver or kidney, uptake transporters are important to consider because they transport compounds from outside to inside of the cell.

Why are drug transporters important?

Drug transporters can be thought of as the A, D, and E in ADME. They are responsible for:

• Absorption
• Distribution
• Tissue-specific drug targeting
• Elimination of compounds

Since drug transporters are so involved in the movement of drugs and compounds, they can be involved in many DDIs. The clearance of transporter substrates (Victims) can be impacted by transporter inhibitors or inducers (Perpetrators) and this can lead to toxicity or loss of efficacy of a given drug.

One example of this is statins. Statins perform their function in the liver and require OATPs to enter into hepatocytes. Cyclosporin is a potent inhibitor of OATP transporters. Therefore, if you’re taking cyclosporin and statins at the same time, you can see a large increase in statin exposure. This can lead to toxic side effects such as rhabdomyolysis, where the muscles break down and release their contents into the bloodstream, which can eventually lead to kidney failure and possibly death.

Regulatory Guidance on Transporters

The regulatory guidance has very clear recommendations when evaluating transporters for drug-drug interactions. The FDA, EMA, and PMDA generally overlap for the 9 main transporters that should be investigated. These include the efflux transporters P-gp and BCRP along with uptake transporters OATP1B1/1B3, OAT1/3, OCT2, and MATE1/2K. Regulatory guidance also recommends that other transporters should be considered as necessary, including BSEP, MRP2, and OCT1.

All of the regulatory agencies recommend that P-gp and BCRP substrate potential should be evaluated. The substrate potential for other transporters should also be considered based on the clearance/elimination routes and/or knowledge of other drugs that are in the same therapeutic class. For example, if the clearance of the compound is 25% or greater through a given elimination pathway, the transporters within that elimination pathway need to be considered for substrate potential of the compound.

For inhibitor evaluation, the FDA guidance for industry recommends that 9 main transporters be investigated, while the EMA recommends 11. In addition, the induction of the transporter P-gp should be considered if the compound is a known inducer for CYP3A4 or for the PXR or CAR pathways. Lastly, any metabolites of the parent drug need to be considered for potential transporter interactions if the metabolite is 25% or more of the parent drug AUC.

In Vitro Drug Transporter Studies

At XenoTech, our definitive transporter studies are designed to meet the requirements of the FDA, EMA and PMDA regulatory agencies. Concentration of solvents is kept low (generally at 0.1%) and going higher than 1% of solvent is avoided. Preliminary experiments that are recommended by FDA guidance, including cytotoxicity, stability of the compound in media, and non-specific binding of the compound to the experimental plates, are included in all definitive study designs. Transporter studies are also offered in a slimmed down, medium-throughput screening (MTS) study design that is useful for lead compound selection.

Drug Transporter Inhibition

The general design of our transporter inhibition studies involves:

• Keeping the probe substrate concentration much lower than the K_m
• Using a short incubation time to keep within linear range while still obtaining acceptable fold uptake of the probe substrate
• Keeping the test article at the highest concentration based on EMA and FDA guidance recommendations while still considering cytotoxicity and solubility limitations

Our definitive design experiment includes 7 concentrations of the test article plus a no-solvent and solvent control in order to determine IC₅₀ should any inhibition be observed. Additionally, we offer a minimal design experiment, which is a MTS design that has 2 concentrations of the test article along with the no-solvent and solvent control. All experiments include the appropriate positive controls with the specific positive control substrates and inhibitors.

Transporter Substrate Potential

Our transporter substrate assays keep the concentration of test article at a pharmacologically relevant concentration, ensuring the concentration is not so low that the compound is below the limit of quantitation or so high that it saturates the transporter, as either of these conditions can make the evaluation of substrate potential difficult.

Definitive study designs include 4 concentrations of test article with 3 time points, and include treatments with or without inhibitor along with the appropriate positive controls.

General Transporter Study Designs

We have three basic designs of our experiments, which depend on the transporter that’s being evaluated:

• ABC Transporter: Efflux Transwell Assays
• SLC Transporter: Uptake Assays
• Vesicles Assays

ABC Transporters: Efflux Transwell Assays

The transwell assay can be thought of as a cup within a cup with a polarized monolayer of cells grow